ArticleActa ophthalmologica2023
Current clinical practice in corneal crosslinking for treatment of progressive keratoconus in four Nordic countries.
Article in Acta ophthalmologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- A randomised controlled trial on cross-linking protocols for the treatment of progressive keratoconus using isoosmolar and hypoosmolar riboflavin with the addition of sterile water in thin corneae.Acta ophthalmologica · 2026Trial
- Early findings in a randomised controlled trial on crosslinking protocols using isoosmolar and hypoosmolar riboflavin for the treatment of progressive keratoconus.Acta ophthalmologica · 2025Trial
- Early findings in a prospective randomised study on three cross-linking treatment protocols: interruption of the iontophoresis treatment protocol.BMJ open ophthalmology · 2023Trial
- The Clinical Significance of the Early Screening of Keratoconus and Its Impact on Maintaining Quality of Life.Life (Basel, Switzerland) · 2026Article
- Diurnal Variations in Anterior Segment Parameters in Different Grades of Patients With Keratoconus.Translational vision science & technology · 2025Article
- Assessing progression limits in different grades of keratoconus from a novel perspective: precision of measurements of the corneal epithelium.Eye and vision (London, England) · 2024Article
- Patient experience and repeatability of measurements made with the Pentacam HR in patients with keratoconus.BMC ophthalmology · 2023Article
- The intra- and inter-day repeatability of corneal densitometry measurements in subjects with keratoconus and in healthy controls.Scientific reports · 2023Article
- Current clinical practice in corneal crosslinking for treatment of progressive keratoconus in four Nordic countries.Acta ophthalmologica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeTo evaluate clinical practice in the diagnosis and treatment of progressive keratoconus with corneal crosslinking (CXL) in four Nordic countries.
methodsA questionnaire was sent to all centres at which keratoconus patients are evaluated and CXL is performed in Sweden, Denmark, Norway and Iceland. Nineteen of 20 centres participated.
resultsCXL is performed approximately 1300 times per year in these four Nordic countries with a population of around 21.7 million (2019). In most cases, progression is evaluated using the Pentacam HR, and the maximum keratometry reading (K
conclusionsWe concluded that the diagnosis of progressive keratoconus and the diagnostic equipment used are similar. Treatment strategies are also similar but are suitably different to provide an interesting basis for the comparison of treatment outcomes. The high degree of participation in this survey indicates the possibility of future scientific collaboration on CXL focusing on the areas deemed to need improvement. It would also be of interest to evaluate the possibility of creating a Nordic CXL Registry. The high number of CXL treatments performed ensures sufficient statistical power to solve many questions. Such a registry could be an important contribution to evidence-based care and would allow for longitudinal evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.